Lv7
4994 积分 2022-11-08 加入
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
3小时前
已完结
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
8天前
已完结
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
8天前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
8天前
已完结
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
15天前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
15天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
15天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
15天前
已完结
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
21天前
已完结
Serplulimab: First Approval
24天前
已完结
皖公网安备34019202002308
